Document:

AMENDMENT NO. 1 TO LICENSE AND COLLABORATION AGREEMENT

                  THIS  AMENDMENT NO. 1 TO LICENSE AND  COLLABORATION  AGREEMENT
(this  "Amendment"),  effective as of September 29, 2000 (the "Effective Date"),
is entered into between THE IMMUNE RESPONSE CORPORATION,  a Delaware corporation
("IRC"),  and  TRINITY  MEDICAL  GROUP  USA,  INC.,  a  Florida  corporation  ("
Trinity"), with respect to the following facts.

                                 R E C I T A L S

                  A. IRC and Trinity  Medical  Group,  Co., Ltd., a Thai limited
company  ("Trinity  Thailand"),  entered  into  the  License  and  Collaboration
Agreement dated as of September 15, 1995 (the "Agreement").

                  B. Pursuant to the Assignment  Agreement  dated as of November
11, 1999,  between Trinity Thailand and Trinity,  Trinity  Thailand  assigned to
Trinity,  and Trinity assumed,  all of Trinity Thailand's rights and obligations
under the Agreement.

                  C. The parties now desire to amend the  Agreement on the terms
and conditions set forth below.

                  NOW, THEREFORE, in consideration of the foregoing premises and
the mutual covenants set forth below, the parties hereby amend the Agreement and
otherwise agree as follows:

                                    ARTICLE 1
                                    AMENDMENT

            1.1 Article 5 of the  Agreement  is amended to insert the  following
new section after the last section thereof:

                  5.7      Trademarks.

                           5.7.1  License.   IRC  hereby  grants  to  Trinity  a
                  non-exclusive,  non-transferable, limited  right to use IRC's
                  trademark  REMUNE(TM)  (the "Mark")  solely for the purpose of
                  promoting, marketing and selling the Product in the Territory.
                  Trinity shall not use the Mark for any other purpose.
<PAGE>

                           5.7.2 Use.  Trinity  shall use the Mark in accordance
                  with  applicable  trademark law and IRC's  policies  regarding
                  advertising  and trademark  usage as  established  and amended
                  from time to time.  Trinity shall not use any other  trademark
                  or service  mark in  proximity  to the Mark  without the prior
                  written approval of IRC.

                           5.7.3  Trademark  Obligations.  Whenever  the Mark is
                  used in  advertising  or in any other  manner,  Trinity  shall
                  clearly indicate IRC as the trademark owner. Trinity shall not
                  do or cause to be done any act or  anything  contesting  or in
                  any way impairing or reducing IRC's right,  title and interest
                  in the  Mark.  Trinity  acknowledges  that  use  of  the  Mark
                  hereunder shall not create any right,  title or interest in or
                  to the use of the Mark and  that  all such  uses and  goodwill
                  associated  with the Mark will  inure to the  benefit  of IRC.
                  Trinity shall take all necessary steps to ensure its employees
                  comply with all the terms and conditions herein.

                           5.7.4 Quality. The nature and quality of any products
                  or services that Trinity  supplies in connection with the Mark
                  shall  conform  to the  standards  set by IRC.  Trinity  shall
                  cooperate  with  IRC  in  facilitating  IRC's  monitoring  and
                  control  of the  nature  and  quality  of  such  products  and
                  services,  and shall  supply IRC with  specimens of use of the
                  Mark  upon  request.   Prior  to  distributing  any  marketing
                  materials or other  literature  containing  the Mark,  Trinity
                  shall  submit a specimen  thereof  to IRC for IRC's  approval.
                  Trinity  shall not  distribute  such  materials or  literature
                  without  prior  written  approval  by IRC.  Should  IRC notify
                  Trinity in writing  that the use of the Mark does not  conform
                  to the standards set by IRC,  Trinity shall have ten (10) days
                  to bring such use into  conformance  and to  provide  IRC with
                  specimens of such conforming use.

                           5.7.5  Infringement  Proceedings.  Trinity  shall use
                  reasonable  efforts to promptly notify IRC of any unauthorized
                  use of the Mark by others that comes to  Trinity's  attention.
                  IRC shall have the sole right and discretion to bring legal or
                  administrative  proceedings to enforce IRC's trademark  rights
                  including   actions  for  trademark   infringement  or  unfair
                  competition proceedings involving the Mark.

                           5.7.6  Trademark  Registrations.  Trinity,  at  IRC's
                  request and  expense,  shall  provide IRC with any  specimens,
                  execute  all   applications   for   trademark   registrations,
                  trademark assignments or similar documents,  and shall perform
                  any other  similar  act  reasonably  necessary  (i) for IRC to
                  secure or  maintain  any and all IRC  trademark  rights in the
                  Territory  or (ii)  to  effectuate  the  lawful  right  to use
                  product names,  designations or trademarks in the Territory as
                  reasonably required by IRC.

            1.2 Section  11.1 of the  Agreement  is restated in its  entirety to
read as follows:

                           Expiration.  Unless  terminated  earlier  pursuant to
                  Sections 11.2 or

                                      -2-

<PAGE>

                  11.3 below, this Agreement shall expire upon the expiration of
                  the last to expire of IRC's  rights in all  patents and patent
                  applications in the Territory which cover the Product.

            1.3 Section  11.2 of the  Agreement  is restated in its  entirety to
read as follows:

                           Termination by IRC. This Agreement  shall  terminate,
                  at the option of IRC effective  upon written notice thereof to
                  Trinity,  if Trinity has not received  the required  marketing
                  approval from the governing  health  authority of Thailand for
                  the  Product  on or before  the first to occur of (a) the date
                  which is eighteen  (18) months  after  receipt of the required
                  marketing  approval  from the FDA for  Product  in the  United
                  States,  and (b) the date  which is  twenty-four  (24)  months
                  after  completion  of the Study  2101B  clinical  trial of the
                  Product in Thailand under the applicable Development Workplan.

                                   ARTICLE 2
                                  MISCELLANEOUS

            2.1  Defined  Terms.  All  terms  used,  but  not  defined,  in this
Amendment shall have the respective meanings set forth in the Agreement.

            2.2 Continuing  Effect.  This  Amendment  shall be effective for all
purposes as of the Effective  Date.  Except as otherwise  expressly  modified by
this  Amendment,  the  Agreement  shall  remain  in full  force  and  effect  in
accordance with its terms.

            2.3 Governing Law. This Amendment shall be governed by and construed
in accordance with the laws of the State of California.

            2.4  Counterparts.  This Amendment may be executed in  counterparts,
each of which shall be deemed to be an original and together  shall be deemed to
be one and the same document.

                                      -3-

<PAGE>

                  IN WITNESS  WHEREOF,  the  undersigned  have duly executed and
delivered this Amendment effective as of the Effective Date.

                                       THE IMMUNE RESPONSE CORPORATION

                                       By: /S/ Dennis J. Carlo, PH.D.
                                          --------------------------------------
                                           Dennis J. Carlo, Ph.D.
                                           President and Chief Executive Officer

                                       TRINITY MEDICAL GROUP USA, INC.

                                       By: /s/ Vina Churdboonchart
                                          --------------------------------------
                                       Title: President
                                            ------------------------------------

                                       By: /s/ James Namnath
                                          --------------------------------------
                                       Title: Chief Executive Officer
                                            ------------------------------------

                                      -4-ASSIGNMENT AGREEMENT

         THIS  ASSIGNMENT  AGREEMENT dated as of August 3, 2000, is entered into
between Trinity Medical Group Co. Ltd., a Thai limited company (the "Assignor"),
and Trinity  Medical Group USA, Inc., a Florida  corporation  (the  "Assignee"),
with respect to the following facts:

         WHEREAS, the Assignor and The Immune Response  Corporation,  a Delaware
corporation ("IRC"),  entered into the License and Collaboration Agreement dated
as of  September  15, 1995 (the  "License  Agreement"),  and the Stock  Purchase
Agreement dated as of September 15, 1995 (the "Stock Purchase Agreement").

         WHEREAS,  the  Assignor  desires to assign all of its right,  title and
interest   in  the  License   Agreement   and  the  Stock   Purchase   Agreement
(collectively,  the  "Agreements")  in connection  with the assignment  from the
Assignor to the Assignee of all of the business of the Assignor  relating to the
Product (as defined in the License Agreement).

         NOW THEREFORE, the parties hereby agree as follows:

         1. The Assignor hereby assigns to the Assignee, and the Assignee hereby
assumes,  all of its rights and  obligations  under the Agreements in connection
with the assignment  from the Assignor to the Assignee of all of the business of
the Assignor relating to the Product.

         2. The Assignee  hereby agrees to be bound by the terms and  conditions
of the  Agreements  to the  same  extent  as if the  Assignee  were an  original
signatory to the Agreements.

         IN WITNESS  WHEREOF,  the parties have caused this Agreement to be duly
executed and delivered effective as of the date first set forth above.

TRINITY MEDICAL GROUP CO., LTD.

By:/s/ Inthanom Churdboonchart            By:/s/ Orranart  Churdboonchart
   ---------------------------------         -----------------------------------

Title: Director                           Title: Director
     -------------------------------             -------------------------------

TRINITY MEDICAL GROUP USA, INC

By:/s/ James S. Namnath                   By: /s/ Vina  Churdboonchart
   ---------------------------------         -----------------------------------

Title: Chief Executive Officer            Title: President
     -------------------------------             -------------------------------

<PAGE>

         IRC hereby consents to the assignment from the Assignor to the Assignee
of all of its  Rights  and  obligations  under the  Agreements  on the terms and
conditions of this Agreement.

                                              THE IMMUNE RESPONSE CORPORATION

                                              By: /s/ Dennis J. Carlo, Ph.D.
                                                 -------------------------------

                                              Title: President and CEO
                                                    ----------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00016-of-00352.parquet"}]]